CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Intracellular Th - ITCI CFD

-
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread -
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* N/A
Open* N/A
1-Year Change* N/A
Day's Range* N/A
52 wk Range 34.43-66
Average Volume (10 days) 0.62379
Average Volume (3 months) 15.0371
Market Cap 5007.06
P/E Ratio N/A
Shares Outstanding 94705100
Revenue 188.116
EPS -3.31566
Dividend (Yield %) N/A
Beta 1.16565
Next Earnings Date Feb 27, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low

Intracellular Th Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 0.3307 0.24584 0 0.06061 22.813 83.803
Revenue 0.3307 0.24584 0 0.06061 22.813 83.803
Total Operating Expense 118.59 103.086 162.267 154.072 254.041 369.491
Selling/General/Admin. Expenses, Total 24.7581 23.667 30.0999 64.9476 186.363 272.611
Research & Development 93.8315 79.419 132.167 89.1248 65.7821 88.8455
Operating Income -118.259 -102.84 -162.267 -154.012 -231.228 -285.688
Interest Income (Expense), Net Non-Operating 2.8983 4.00586 7.14096 6.29127 4.23548 1.56809
Net Income Before Taxes -115.361 -98.8343 -155.126 -147.721 -226.992 -284.12
Net Income After Taxes -116.426 -98.8734 -155.127 -147.722 -227.006 -284.126
Net Income Before Extra. Items -116.426 -98.8734 -155.127 -147.722 -227.006 -284.126
Net Income -116.426 -97.7734 -155.127 -147.722 -227.006 -284.126
Income Available to Common Excl. Extra. Items -116.426 -98.8734 -155.127 -147.722 -227.006 -284.126
Income Available to Common Incl. Extra. Items -116.426 -97.7734 -155.127 -147.722 -227.006 -284.126
Diluted Net Income -116.426 -97.7734 -155.127 -147.722 -227.006 -284.126
Diluted Weighted Average Shares 43.2402 46.1819 54.7079 55.1862 70.3648 81.2534
Diluted EPS Excluding Extraordinary Items -2.69255 -2.14095 -2.83556 -2.6768 -3.22613 -3.49679
Diluted Normalized EPS -2.69255 -2.14095 -2.83556 -2.6768 -3.22613 -3.49679
Total Extraordinary Items 1.1
Dividends per Share - Common Stock Primary Issue 0 0
Cost of Revenue, Total 1.89503 8.03459
Gross Profit 20.9179 75.7684
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 15.8783 20.0466 22.2072 25.6709 34.996
Revenue 15.8783 20.0466 22.2072 25.6709 34.996
Cost of Revenue, Total 1.45522 2.04003 2.00132 2.53803 3.155
Gross Profit 14.4231 18.0065 20.2059 23.1329 31.841
Total Operating Expense 69.097 89.1876 99.531 111.675 107.658
Selling/General/Admin. Expenses, Total 52.5836 69.8512 70.4979 79.6784 75.46
Research & Development 15.0582 17.2964 27.0318 29.4591 29.043
Operating Income -53.2187 -69.1411 -77.3238 -86.0045 -72.662
Interest Income (Expense), Net Non-Operating 0.48375 0.42103 0.3927 0.27062 0.548
Net Income Before Taxes -52.7349 -68.72 -76.9311 -85.7339 -72.114
Net Income After Taxes -52.7399 -68.7438 -76.908 -85.7339 -72.119
Net Income Before Extra. Items -52.7399 -68.7438 -76.908 -85.7339 -72.119
Net Income -52.7399 -68.7438 -76.908 -85.7339 -72.119
Income Available to Common Excl. Extra. Items -52.7399 -68.7438 -76.908 -85.7339 -72.119
Income Available to Common Incl. Extra. Items -52.7399 -68.7438 -76.908 -85.7339 -72.119
Diluted Net Income -52.7399 -68.7438 -76.908 -85.7339 -72.119
Diluted Weighted Average Shares 80.9464 81.2298 81.3547 81.4781 92.6043
Diluted EPS Excluding Extraordinary Items -0.65154 -0.84629 -0.94534 -1.05223 -0.77879
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.65154 -0.84629 -0.94534 -1.05223 -0.77879
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 388.2 469.215 355.439 230.324 690.904 467.281
Cash and Short Term Investments 384.101 464.331 347.531 224.01 657.448 412.333
Cash & Equivalents 48.6422 37.7901 54.9475 107.637 60.0459 92.365
Short Term Investments 335.458 426.541 292.583 116.373 597.402 319.968
Total Receivables, Net 0.09434 0 10.7646 20.156
Accounts Receivable - Trade, Net 0.09434 0 10.7646 20.156
Prepaid Expenses 4.00509 4.88429 7.90813 6.31379 14.2355 25.4434
Total Assets 388.904 471.487 357.207 251.186 717.314 489.922
Property/Plant/Equipment, Total - Net 0.62761 1.13717 1.15977 20.5118 26.3231 22.5552
Property/Plant/Equipment, Total - Gross 3.17638 3.82996 4.19369 24.0203 30.3597 27.1238
Accumulated Depreciation, Total -2.54877 -2.69279 -3.03392 -3.50843 -4.03655 -4.56867
Other Long Term Assets, Total 0.07577 1.1342 0.60805 0.35069 0.08608 0.08608
Total Current Liabilities 10.5323 14.2096 36.2992 36.224 36.8532 53.3565
Accounts Payable 3.75465 6.17354 13.9611 7.42502 5.50183 8.69122
Accrued Expenses 6.77769 8.03607 22.3381 28.799 31.3514 44.6653
Notes Payable/Short Term Debt 0 0 0 0 0 0
Total Liabilities 13.401 17.0497 39.4916 56.1792 60.4536 72.0314
Total Long Term Debt 0 0 0 0 0 0
Other Liabilities, Total 2.86862 2.84013 3.19243 19.9552 23.6003 18.6749
Total Equity 375.503 454.437 317.715 195.007 656.86 417.891
Common Stock 0.00433 0.00546 0.00549 0.00555 0.00805 0.00819
Additional Paid-In Capital 685.291 862.479 880.753 904.972 1593.48 1639.48
Retained Earnings (Accumulated Deficit) -309.475 -407.249 -562.376 -710.098 -937.104 -1221.23
Other Equity, Total -0.31724 -0.79922 -0.66776 0.12832 0.48058 -0.36365
Total Liabilities & Shareholders’ Equity 388.904 471.487 357.207 251.186 717.314 489.922
Total Common Shares Outstanding 43.2929 54.5977 54.8953 55.5075 80.4631 81.887
Total Inventory 7.05639 7.94813
Other Current Assets, Total 1.4 1.4
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 649.1 601.303 533.243 467.281 848.342
Cash and Short Term Investments 611.965 554.757 477.284 412.333 771.848
Cash & Equivalents 129.98 121.03 106.126 92.365 129.295
Short Term Investments 481.985 433.727 371.158 319.968 642.553
Total Receivables, Net 13.662 15.1878 16.9343 20.156 32.832
Accounts Receivable - Trade, Net 13.662 15.1878 16.9343 20.156 32.832
Total Inventory 7.57939 7.76885 8.16694 7.94813 7.893
Prepaid Expenses 14.4944 22.1892 29.4575 25.4434 34.369
Other Current Assets, Total 1.4 1.4 1.4 1.4 1.4
Total Assets 674.489 625.697 556.976 489.922 868.58
Property/Plant/Equipment, Total - Net 25.302 24.3073 23.647 22.5552 20.152
Property/Plant/Equipment, Total - Gross 29.4656 28.5965 28.0701 27.1238
Accumulated Depreciation, Total -4.16356 -4.28914 -4.42308 -4.56867
Other Long Term Assets, Total 0.08608 0.08608 0.08608 0.08608 0.086
Total Current Liabilities 39.7017 50.4219 49.8956 53.3565 59.074
Accounts Payable 8.72096 15.9408 12.0306 8.69122 11.649
Accrued Expenses 30.9807 34.4812 37.8649 44.6653 47.425
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 62.3388 72.1108 70.2195 72.0314 75.83
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 22.6371 21.6889 20.3239 18.6749 16.756
Total Equity 612.15 553.586 486.756 417.891 792.75
Common Stock 0.00811 0.00813 0.00814 0.00819 0.009
Additional Paid-In Capital 1601.74 1611.99 1622.15 1639.48 2089.42
Retained Earnings (Accumulated Deficit) -989.844 -1058.59 -1135.5 -1221.23 -1293.35
Other Equity, Total 0.24655 0.17612 0.0942 -0.36365 -3.328
Total Liabilities & Shareholders’ Equity 674.489 625.697 556.976 489.922 868.58
Total Common Shares Outstanding 81.1339 81.3119 81.3774 81.887 94.0204
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -116.426 -97.7734 -155.127 -147.722 -227.006 -284.126
Cash From Operating Activities -91.2572 -80.4918 -118.169 -127.983 -230.073 -259.543
Cash From Operating Activities 0.19687 0.21387 0.36867 0.47712 0.52812 0.53336
Non-Cash Items 15.4794 15.2622 16.6454 19.8513 23.681 30.4017
Cash Taxes Paid 1 0 0.0016 0.0016 0.0016 0.00563
Cash Interest Paid 0.03678 0 0 0
Changes in Working Capital 9.49282 2.86392 19.415 -0.85409 -27.541 -6.35291
Cash From Investing Activities 92.2624 -92.7177 134.641 177.437 -480.295 280.344
Capital Expenditures -0.04896 -0.72343 -0.39127 -0.7004 -0.26672 -0.32574
Other Investing Cash Flow Items, Total 92.3114 -91.9943 135.033 178.137 -480.028 280.669
Cash From Financing Activities 0.47773 162.357 0.68519 3.2356 664.177 11.5189
Financing Cash Flow Items 0
Issuance (Retirement) of Stock, Net 0.47773 162.357 0.68519 3.2356 664.177 11.5189
Issuance (Retirement) of Debt, Net 0 0 0
Net Change in Cash 1.48292 -10.8521 17.1574 52.6894 -46.1909 32.3191
Deferred Taxes -1.05844 0.52922 0.26461 0.26461 0
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -52.7399 -121.484 -198.392 -284.126 -72.119
Cash From Operating Activities -47.7669 -107.092 -186.359 -259.543 -82.849
Cash From Operating Activities 0.12701 0.25259 0.38653 0.53336 0.171
Deferred Taxes 0 0 0 0
Non-Cash Items 5.74603 13.7927 21.7686 30.4017 4.05
Changes in Working Capital -0.90005 0.34621 -10.1223 -6.35291 -14.951
Cash From Investing Activities 116.269 165.063 228.834 280.344 -322.035
Capital Expenditures 0 -0.01524 -0.3245 -0.32574 -0.566
Other Investing Cash Flow Items, Total 116.269 165.078 229.159 280.669 -321.469
Cash From Financing Activities 1.43166 3.01336 3.60465 11.5189 441.814
Issuance (Retirement) of Stock, Net 1.43166 3.01336 3.60465 11.5189 441.814
Net Change in Cash 69.934 60.9842 46.08 32.3191 36.93
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Fidelity Management & Research Company LLC Investment Advisor 10.8374 10263601 -63066 2022-09-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 8.5536 8100645 35822 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 6.2974 5963976 -49824 2022-09-30 LOW
Wasatch Global Investors Inc Investment Advisor/Hedge Fund 5.5364 5243290 -147775 2022-09-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 5.4472 5158750 695392 2022-09-30 LOW
Alafi Capital Company, LLC Venture Capital 5.009 4743770 0 2022-04-01 LOW
Bellevue Asset Management AG Investment Advisor 3.5154 3329279 -20100 2022-09-30 LOW
AllianceBernstein L.P. Investment Advisor/Hedge Fund 2.3234 2200408 87821 2022-09-30 LOW
Lord, Abbett & Co. LLC Investment Advisor 2.1316 2018686 167737 2022-09-30 MED
State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.0867 1976223 56408 2022-09-30 LOW
Millennium Management LLC Hedge Fund 1.944 1841049 803772 2022-09-30 HIGH
Franklin Advisers, Inc. Investment Advisor/Hedge Fund 1.8837 1783950 97480 2022-09-30 LOW
Invesco Advisers, Inc. Investment Advisor 1.7467 1654221 1002967 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.7088 1618310 29911 2022-09-30 LOW
Holocene Advisors, LP Hedge Fund 1.6804 1591383 -36025 2022-09-30 HIGH
GW&K Investment Management, LLC Investment Advisor 1.5478 1465835 882242 2022-09-30 LOW
Avidity Partners Management LP Hedge Fund 1.4809 1402500 626996 2022-09-30 HIGH
Mates (Sharon) Individual Investor 1.1557 1094467 -38925 2022-04-01 LOW
TimesSquare Capital Management, LLC Investment Advisor 0.935 885510 84672 2022-09-30 LOW
Schroder Investment Management North America Inc. Investment Advisor 0.9266 877537 37021 2022-09-30 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
480000+

Traders

75000+

Active clients monthly

$52000000+

Monthly investing volume

$34000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Intracellular Th Company profile

About Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company provides CAPLYTA (lumateperone) for the treatment of schizophrenia in adults. The CAPLYTA is a prescription medicine used to treat the depressive episodes in adults with bipolar I or II, that can be taken alone or with lithium or valproate. The Company's pipeline is focused on three platforms: lumateperone and follow-on compounds, a phosphodiesterase 1 (PDE1) inhibitor platform and discovery platform which includes ITI-333 a novel compound with high affinity at serotonin 5-HT2A, dopamine D1 and mu opioid (MOP) receptors. The Company’s subsidiaries are ITI, Inc. (ITI) and ITI Limited.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Intra-Cellular Therapies Inc revenues increased from $22.8M to $83.8M. Net loss increased 25% to $284.1M. Revenues reflect Product sales increase from $22.5M to $81.7M, Grant revenue increase from $282K to $2.1M. Higher net loss reflects General & admin increase of 46% to $249.8M (expense), Research and development increase of 35% to $79M (expense).

Industry: Bio Therapeutic Drugs

430 East 29Th Street
NEW YORK
NEW YORK 10016
US

Income Statement

People also watch

US100

11,610.80 Price
-0.360% 1D Chg, %
Long position overnight fee -0.0163%
Short position overnight fee 0.0058%
Overnight fee time 22:00 (UTC)
Spread 1.8

XRP/USD

0.39 Price
-1.380% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00357

Oil - Crude

72.66 Price
-0.060% 1D Chg, %
Long position overnight fee -0.0086%
Short position overnight fee -0.0054%
Overnight fee time 22:00 (UTC)
Spread 0.03

Natural Gas

6.26 Price
+5.630% 1D Chg, %
Long position overnight fee 0.0552%
Short position overnight fee -0.0826%
Overnight fee time 22:00 (UTC)
Spread 0.005

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading